Results 31 to 40 of about 10,001 (276)

Terlipressin infusion for prevention of vasoplegic syndrome in patients treated with angiotensin II receptor antagonist undergoing coronary artery bypass graft surgery: a randomized controlled study

Ain Shams Journal of Anesthesiology, 2020
Background and objectives Preoperative use of renin angiotensin system antagonists has been considered an independent risk factor for development of vasoplegic syndrome.
Mohamed Saleh, Sherine Kamal Zaki Kodeira, Abdelkhalek Abdelmoneim Aboulseoud   +2 more
doaj   +1 more source

Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies [PDF]

, 2017
Background The goal of hepatorenal syndrome type 1 (HRS-1) treatment is to improve renal function. Terlipressin, a synthetic vasopressin analogue, is a systemic vasoconstrictor used for the treatment of HRS-1, where it is available.
Araya, V., Boyer, T. D., Escalante, S., Frederick, R. T., Jamil, K., Pappas, S. C., Reddy, K. R., Rossaro, L., Sanyal, A. J., Teuber, P., Vargas, H. E., Wong, F.   +11 more
core   +2 more sources

Safety and efficacy of continuous infusion terlipressin (BIV201): A phase 2 trial in patients with decompensated cirrhosis and refractory ascites. [PDF]

Liver Transpl
Bajaj JS, Weinberg EM, Reddy KR, Keaveny AP, Porayko MK, Koch D, Thuluvath PJ, Simonetto DA, Angeli P, Janardhan SV, Orman ES, Zhang J, Clausen S, Dauphinée E, Palumbo JM, Markham P.   +15 more
europepmc   +2 more sources

Improvement of gut-vascular barrier by terlipressin reduces bacterial translocation and remote organ injuries in gut-derived sepsis

Frontiers in Pharmacology, 2022
Gut-vascular barrier (GVB) serves as the last barrier to limit the migration of intestinal toxins into the blood circulation. The efficacy of terlipressin (a vasopressin V1 receptor agonist) in reducing GVB and multiple organ damage in gut-derived sepsis
Zenan Chang, Zenan Chang, Yinan Zhang, Ming Lin, Shihong Wen, Hanjin Lai, Yaqing Zhan, Xiufen Zhu, Zhikun Huang, Xuyu Zhang, Zimeng Liu   +10 more
doaj   +1 more source

Terlipressin or Europressin? [PDF]

Critical Care, 2009
Use of terlipressin in septic shock relies on a series of European studies resulting in a better knowledge of this vasopressive agent. Additional studies demonstrate that this agent appears to have attractive properties when administered properly.
openaire   +2 more sources

Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis [PDF]

, 2007
Hepatorenal syndrome (HRS) is a serious complication of end-stage liver disease, occurring mainly in patients with advanced cirrhosis and ascites, who have marked circulatory dysfunction,1 as well as in patients with acute liver failure.2 In spite of its
Angeli P, Arroyo V, BERNARDI, MAURO, Blendis L, Di Bona G, Garcia Tsao G, Gerbes A, Ginès P, Guevara M, Gülberg V, Henriksen JH, Kamath P, Lee S, Moore K, Moreau R, Mullen K, Ortega R, Ruiz del Arbol L, Salerno F, Sanyal A, Terg R., Wong F   +21 more
core   +4 more sources

A rare and threatening complication in a cirrhotic patient [PDF]

, 2018
info:eu-repo/semantics ...
Anapaz, V, Branco, J, Reis, J, Santos, L
core   +1 more source

Terlipressin or norepinephrine in septic shock: do we have the answer? [PDF]

, 2019
Comment on Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial.
Russell, James A., Williams, Mark D.
core   +1 more source

The effects of vasopressin and its analogues on the liver and its disorders in the critically ill: [PDF]

, 2010
Purpose of review: Vasopressin and terlipressin, a long-acting V1a analogue, are increasingly used in intensive care. The main clinical indications are the treatment of patients with septic shock and of patients with cirrhosis, who develop variceal ...
F. Oberti, P. Asfar, P. Calès, P. Radermacher   +3 more
core   +2 more sources

Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1 [PDF]

, 2017
Background Hepatorenal syndrome type 1 (HRS1) is a functional, rapidly progressive, potentially reversible form of acute kidney injury occurring in patients with cirrhosis.
Alessandria, Angeli, Arroyo, Belcher, Belcher, Besso, Boyer, Cavallin, Fernández, Gillies, Gluud, Hadengue, Mandal, Marik, Martin-Llahi, Martin-Llahi, Mattos, Moher, Navasa, Neri, Newby, Platt, Ruiz-del-Arbol, Salerno, Salerno, Salmeron, Sanyal, Schepke, Sharma, Silawat, Singh, Solanki, Srivastava, Tavakkoli, Wood   +34 more
core   +3 more sources